We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Twenty-two prescription medicines have been added to the Kmart Pharmacy discount program that offers a 90-day supply of generic drugs for a flat rate of $15, Sears Holdings announced.
More states are set to participate in Wal-Mart’s $4 prescription drug program as the company announced yet another expansion that will add 11 states and 17 prescription drugs to the plan.
The attorneys general of California and Alaska have issued subpoenas to AstraZeneca seeking information about its marketing practices for Seroquel (quetiapine fumarate), and the SEC has made an “informal inquiry” to the company regarding payments to foreign doctors and government officials, the company said.
An additional 3.8 million people without prescription drug coverage will be eligible for free drugs from AstraZeneca thanks to an expansion in the company’s Patient Assistance Program.
Retail giant Wal-Mart is expanding its generic drug discount program to the entire state of Florida four months ahead of schedule and adding to the list of drugs included in the program, but one analyst is questioning the move’s impact on the market.
Retail giant Wal-Mart is expanding its generic drug discount program to the entire state of Florida four months ahead of schedule and adding to the list of drugs included in the program, but one analyst is questioning the move’s impact on the market.
Drugstores are scrambling to defend their generic drug pricing policies following Wal-Mart’s announcement it would decrease the price of nearly 300 generic medicines to $4 for a 30-day supply.
The world’s largest retailer plans to slash the prices of close to 300 generic drugs to $4 for a month’s supply, in what is likely the biggest promotion ever to buy cheaper generic alternatives to brand drugs.
The FTC has announced it will conduct a study on the competitive effects of authorized generics, the latest in a string of actions that shows the commission is taking a harder line on potentially anticompetitive agreements between drugmakers.